CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content

Drug Reimbursement Recommendation - upadacitinib (Rinvoq)

Published on: February 6, 2020
Result type: News

Today, CADTH has issued final recommendations for:

upadacitinib (Rinvoq)

Indications: Arthritis, Rheumatoid
Recommendation: Reimburse with clinical criteria and/or conditions

For more information